{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:30:46Z","timestamp":1776922246185,"version":"3.51.2"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CAD"],"published-print":{"date-parts":[[2021,1,18]]},"abstract":"<jats:sec>\n<jats:title>Aims:<\/jats:title>\n<jats:p>Discovery of new Glo-I inhibitors as potential anticancer agents.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p> Glyoxalase system is ubiquitous system in human cells which has been examined\nthoroughly for its role in cancerous diseases. It performs detoxifying endogenous harmful metabolites,\nmainly methylglyoxal (MG) into non-toxic bystanders.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>Structure based model Hypo(2ZA0_2_02) combined with 3D-QSAR modeling were\napplied to predict glyoxalase I inhibition and to explain their activity.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Currently, high throughput screening approach was used to investigate the activity of inhouse\ndatabase composed of 205 compounds.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Result:<\/jats:title>\n<jats:p>15 compounds were found active as glyoxalase I inhibitors. The 15 candidates showed\nmore than 50% inhibition with low micromolar IC50 ranges between 5.0 to 42.0 \u03bcM.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>They have been successfully mapped and fitted the Hypo(2ZA0_2_02) model which\nexplain the presence of anti-glyoxalase I activity.\nThis model could be used in future for further development of new and novel glyoxylase I inhibitors.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573409916666200117100326","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T11:34:29Z","timestamp":1579520069000},"page":"814-832","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Combined High Throughput Screening with QSAR Analysis Unravelling Potential Glyoxalase-I Inhibitors"],"prefix":"10.2174","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9962-1971","authenticated-orcid":true,"given":"Mahmoud A.","family":"Al-Sha\u2019er","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Zarqa University, Zarqa 13132, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8350-900X","authenticated-orcid":true,"given":"Qosay A.","family":"Al-Balas","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4427-958X","authenticated-orcid":true,"given":"Mohammad A.","family":"Hassan","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Current Computer-Aided Drug Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/178386","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/178386\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/178386","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T06:01:04Z","timestamp":1611036064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/178386\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,18]]},"references-count":0,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,1,18]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573409916666200117100326","relation":{},"ISSN":["1573-4099"],"issn-type":[{"value":"1573-4099","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,18]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-10-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}